RAPSODI: RAPid SOlution for Diagnosis of Respiratory Infection in Pediatric Intensive Care Unit

Sponsor
Assistance Publique - Hôpitaux de Paris (Other)
Overall Status
Completed
CT.gov ID
NCT04773704
Collaborator
(none)
36
1
8.7
4.2

Study Details

Study Description

Brief Summary

In patients with infectious pneumonitis, the FILMARRAY® Pneumonia Plus Panel technique (multiplex PCR) on a respiratory sample makes it possible to identify the responsible pathogen and its resistance to antibiotics in less than an hour and therefore to quickly adapt the anti- infectious. FILMARRAY® Pneumonia Plus has been validated on two types of specimens from adult intubated patients, tracheal aspirations and bronchoalveolar lavage. It has not been validated on protected distal samples which are nevertheless used in current practice. This project will study the diagnostic validity of this technique performed on this type of sample. If the validity is demonstrated, this will allow this technique to be used on the protected distal sample which is a reliable sample and used in the context of respiratory infections, in particular acquired under ventilation in children (bronchoalveolar lavage is less easy and little used in practice in children).

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: FILMARRAY® Pneumonia Plus Panel technique

Detailed Description

In patients with infectious pneumonitis, the FILMARRAY® Pneumonia Plus Panel technique (multiplex PCR) on a respiratory sample makes it possible to identify the responsible pathogen and its resistance to antibiotics in less than an hour and therefore to quickly adapt the anti- infectious. FILMARRAY® Pneumonia Plus has been validated on two types of specimens from adult intubated patients, tracheal aspirations and bronchoalveolar lavage. It has not been validated on protected distal samples which are nevertheless used in current practice. This project will study the diagnostic validity of this technique performed on this type of sample. If the validity is demonstrated, this will allow this technique to be used on the protected distal sample which is a reliable sample and used in the context of respiratory infections, in particular acquired under ventilation in children (bronchoalveolar lavage is less easy and little used in practice in children).

As a result, this will allow a faster etiological diagnosis and adapted antibiotic therapy, guaranteeing better efficacy and a fairer antibiotic prescription.

Currently no studies concerning the FILMARRAY® Pneumonia Plus Panel are ongoing or have been performed with the protected distal samples.

This study would be innovative and unique in looking at its feasibility and validity on a type of sample used in current practice.

In addition, the use of a PCR-based technique allows a rapid microbiological diagnosis of lower respiratory infections under invasive mechanical ventilation, compared to the reference technique requiring 48 to 72 hours to give a definitive result.

This much shorter period allows for an appropriate antibiotic therapy early in the treatment, and potentially a reduction in ventilation and hospitalization times.

In addition, it detects antibiotic resistance genes allowing rapid identification of multi-resistant bacteria (resistant Staphylococcus aureus meticillin, enterobacteria producing ESBLs or carbapenemases) and thus adapting antibiotic therapy.

Our study will assess its diagnostic validity for the identification of the microorganisms responsible for pneumonia in intensive care and their resistance to antibiotics.

Study Design

Study Type:
Observational
Actual Enrollment :
36 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Diagnostic Validity of a New Strategy for the Rapid Detection of Microorganisms and Their Resistance to Antibiotics Responsible for Pneumonia in Pediatric Intensive Care Units Using Protected Distal Samples
Actual Study Start Date :
Apr 29, 2021
Actual Primary Completion Date :
Jan 18, 2022
Actual Study Completion Date :
Jan 18, 2022

Outcome Measures

Primary Outcome Measures

  1. concordance between the results of the FILMARRAY® Pneumonia on a protected distal sample (new strategy) and those obtained by culture and antibiogram (classic diagnosis, reference method) [1 week]

    Percentage of diagnostic agreement between the FilmArray result carried out on protected distal samples and the result of the reference method and description of the microorganisms most frequently found in cases of discrepancies.

Secondary Outcome Measures

  1. To establish the percentage of invalid analyzes on this type of sample. [24 months]

    Number of invalid analyzes out of the total number of analyzes performed on protected sample with the FilmArray.

  2. Rate of true positives (agreement of positive results between new strategy and reference method) [24 months]

  3. Rate of true negatives (agreement of negative results between new strategy and reference method). [24 months]

  4. To establish the diagnostic time saving in real life use. [24 months]

    Differential in final rendering time between the new strategy and the reference method.

  5. Number of diagnoses adjusted on the number of diagnoses sought in children whose sample was taken after antibiotic therapy. [24 months]

    Number of diagnoses adjusted on the number of diagnoses sought in children whose sample was taken after antibiotic therapy.

Eligibility Criteria

Criteria

Ages Eligible for Study:
1 Day to 18 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patients hospitalized in pediatric intensive care

  • Patients under mechanical ventilation (intubated or tracheostomized)

  • Age <18 years old

Exclusion Criteria:
  • Contraindications to protected distal sampling

  • Refusal to participate by at least one parent or legal guardian(s)

  • Patient not covered by health insurance

Contacts and Locations

Locations

Site City State Country Postal Code
1 Robert Debré Hospital Paris France 75019

Sponsors and Collaborators

  • Assistance Publique - Hôpitaux de Paris

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Assistance Publique - Hôpitaux de Paris
ClinicalTrials.gov Identifier:
NCT04773704
Other Study ID Numbers:
  • APHP20132
First Posted:
Feb 26, 2021
Last Update Posted:
Jan 31, 2022
Last Verified:
Feb 1, 2021
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Assistance Publique - Hôpitaux de Paris
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 31, 2022